The aggressiveness of human gliomas appears to be correlated with the upregulation of interleukin 6 (IL-6) gene. Using quantitative PCR methods, we detected amplification and expression of the IL-6 gene in 5 of 5 primary glioblastoma samples and in 4 of 5 glioblastoma cell lines. This finding suggests that the amplification of IL-6 gene may be a common feature in glioblastomas and may contribute to the IL-6 over-expression.
The release of biologically active interleukin 6 (IL-6) frequently occurs in human glioblastomas, the most malignant brain tumours (Van Meir et al, 1990 ). In our previous study on a large series of 59 gliomas, we have demonstrated a strong association between the aggressiveness of glial tumours and degree of IL-6 expression at the RNA level (Rolhion et al, 2001) . As IL-6 has properties of a growth factor for tumour cells (Goswami et al, 1998) and is able to block apoptosis induced by various chemotherapeutic compounds (Borsellino et al, 1995) or reactive oxygen species (Miwa et al, 2000) , the expression of the IL-6 gene may be one of the most important factors contributing to the growth and survival of glioblastoma cells in patients under radiotherapy and chemotherapy.
The mechanism underlying the IL-6 upregulation in glioblastoma still remains unclear. The results of molecular cytogenetics in glioblastoma point to frequent gains of chromosome 7 and amplification events on 7p (Weber et al, 1996) . Since the IL-6 gene is located on 7p21, the up-regulation of IL-6 expression in tumour cells could be mediated by amplification of the gene. In order to test this hypothesis, we determined the number of IL-6 gene copies and IL-6 mRNA levels in glioblastoma cell lines and primary cells using quantitative PCR assays.
MATERIAL AND METHODS

Tumour material
Five glioblastoma cell lines including SF763 and SF767 (Joy et al, 1997) , U87 and U251 (van Meir et al, 1994) and G5 (Buronfosse et al, 1994) were used in this study. In addition, five samples of primary tumour cells were obtained from patients with glioblastoma who underwent surgery.
DNA and RNA extraction, cDNA preparation DNA and total RNAs were extracted using Trizol ® reagent (GIBCO/BRL, Grand Island, NY), according to the manufacturer's instructions. Reverse transcription of RNA was performed as described elsewhere (Rolhion et al, 1999) .
Competitive IL-6 gene dosage assay
The IL-6 competitor was produced from normal human genomic DNA using the PCR amplification method with a composite primer (Celi et al, 1993) . The conventional and composite IL-6 primers were derived from the IL-6 gene sequence (Yasukawak et al, 1987) as follows: ILF, 5′-AATTCGGTACATCCTCGACGG-3′ (forward); ILR, 5′-GGGCATGGATTTCAGACCC-3′ (reverse); ILAILR, 5′-GGGCATGGATTTCAGACCCCAGTCTAG-GTCGTTGGCCTCA-3′ (composite primer). Schematic diagram illustrating the generation of the competitor is presented in Figure  1A . Constant amounts of target DNA and serially diluted competitor were co-amplified using the ILF/ILR primers. After the separation on a 2%-agarose gel, the yields of amplified competitor and target products were analysed and quantified using the Imager Gel Documentation System (Appligene Oncor, Illkirch, France). The amount of IL-6 molecules in the sample per nanogram of DNA was calculated from the equivalence point where the amount of amplified target was equal to the amount of amplified IL-6 competitor ( Figure 1B) . The relative changes in the number of IL-6 copies in tumour DNA were estimated in comparison with normal human DNA used as a reference in each PCR experiment ( Figure 1C ).
Real-time PCR analysis of gene dosage
We quantitated IL-6 gene dosage using real-time PCR in the LightCycler system (Roche Diagnostics, Meylan, France). The amplification of IL-6 gene was performed using ILF/ILR primers and a DNA Master SYBRGreen I reagent set (Roche Diagnostics).
In parallel in the same samples, we assessed the dosage of another gene from chromosome 7, the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on 7q31.2. The amplification of CFTR gene was performed using the primers described by Dean et al (1990) . To provide a genomic reference point for each sample, the copy number of beta-globin gene, which is located on chromosome 11 (11p15.5), was determined. The region 11p15.5 has not been reported to be involved in chromosomal gains and losses observed in human glioblastomas (Schlegel et al, 1996; Nishizaki et al, 1998) . The sequences of beta globin genespecific primers were as follows: forward, 5′-GGTTGGCCAATC-TACTCCCAG-3′; reverse, 5′-GCTCACTCAGTGTGGCAAAG-3′. For dosage analysis of each gene, calibration curves were constructed with serial dilutions of purified specific PCR products which contained known numbers of DNA molecules. The results of realtime PCR were expressed as a ratio of the copy number determined for the target gene (IL-6 or CFTR) to the copy number of the control gene, beta globin.
Semiquantitative RT-PCR for IL-6 mRNA with an endogenous standard IL-6 mRNA levels were assessed using a semiquantitative RT-PCR as described in details previously (Rolhion et al, 1999) . In this approach, the ratio expression rate (RER) of IL-6 to β2-microglobulin genes was determined.
Real-time RT-PCR for IL-6 mRNA
To quantitate IL-6 mRNA, fluorescent TaqMan methodology and ABl Prism 7700 Sequence Detection System (Perkin Elmer Applied Biosystems, Courtaboeuf, France) were used. A relative quantitation was made with the comparative threshold cycles (∆ ∆ C T ) method (PE User Bulletin #2, 1997) where the amount of IL-6 target was normalized to an endogenous reference, the 18S rRNA gene, and relative to a calibrator, the U251 glioblastoma cell line. The following amplification primers and probes were used: IL-6 forward primer 5′-TGAACTCCTTCTCCACAAGCG-3′; reverse primer 5′-TCTGAAGAGGTGAGTGGCTGTC-3′ and labelled probe 5′-TGGTGTTGCCTGCTGTCCCT-3′; 18S rRNA gene forward primer 5′-CGGCTACCACATCCAAGGAA-3′, reverse primer 5′-GCTGGAATTACCGCGGCT-3′ and probe 5′-TGCTG-GCACCAGACTTGCCCT-3′.
RESULTS
IL-6 gene dosage
We first quantified the number of IL-6 gene copies in DNA samples using competitive PCR. In 5 control human genomic DNA samples, this method determined a mean number of 226 (± 45, SD) IL-6 gene molecules/ng of DNA. In most DNA samples obtained from glioblastoma cells, the dosage of IL-6 gene was found to be elevated, varying between 335 to 1135 gene molecules/ng of DNA (mean, 719 ± 295). The IL-6 gene copy-number ratio of tumour DNA to normal DNA varied from 1.58 to 4.87 (Table 1) .
As the increase in IL-6 gene dosage was relatively low, we developed a sensitive real-time PCR strategy to confirm the findings of competitive PCR. The real-time PCR analysis demonstrated levels of IL-6 gene over-representation that were similar to those obtained with competitive PCR (Table 1) . A highly significant correlation was found between the results of two methods (r = 0.94, P < 0.001). Interestingly, according to the results of both methods, IL-6 gene over-representation was higher in primary glioblastoma cells than in cell lines.
To investigate the possibility that the increased dosage of IL-6 gene on 7p was due to a gain of the whole chromosome 7, we determined the dosage of CFTR gene located on chromosome 7q. As shown in Figure 3 , the dosage of CFTR gene in tumour DNA was elevated approximately 1.6-fold in GBM1 and GBM3 Figure 1 (A) Construction of the IL-6 DNA competitor. Note that the 3′ end of the composite primer ILAILR (segment ILA) corresponds to the opposite strand of the target sequence at a predetermined distance from the primer ILF, and the 5′ end is identical to the sequence of the primer ILR, whose binding site is located 43 bp upstream from the segment ILR.
(B) Co-amplification of serial dilutions of competitor with a constant amount of normal human DNA using ILF/ILR primers, spanning exon 2/intron 2 of the IL-6 gene. The number of competitor molecules added is shown above each lane. Two amplification products are generated, one derived from the target DNA (IL-6) and another one, 62 bp smaller, derived from the competitor (COMP). The equivalence point, at which competitor and target bands would have the same intensity, is indicated by an arrow. M, PCR markers (Promega). (C) Quantitation of IL-6 gene copies present in control and glioblastoma (SF763 cell line) DNA samples using competitive PCR. The equivalence points between the competitor and sample bands corresponded to 10 3.9 and 10 4.4 competitor molecules as determined by means of densitometry. Compensation for the difference in size between the competitor and sample bands was made by multiplying the number of competitor molecules at equivalence point by 0.76. The amounts of DNA used for PCR being known, the numbers of competitor molecules at equivalence point were converted into the numbers of IL-6 molecules per ng DNA: 221 for normal DNA sample and 633 for SF763 DNA sample. M, PCR markers (Promega) tumours, and in U251 cell line, suggesting a trisomy 7; and 2.2-fold in the GBM4 tumour, indicating either a tetrasomy 7 or a lowlevel amplification involving 7q31.2 chromosomal region. The SF763 cell line demonstrated an underrepresentation of CFTR gene of about 50%. CFTR gene dosage was found to be identical to that of normal DNA in the remaining primary tumours and cell lines. Overall, the dosage of IL-6 gene was higher than that of CFTR gene in most glioblastoma samples. 
IL-6 gene expression
IL-6 expression at the RNA level was studied using two quantitative RT-PCR-based methods (Table 1) . The results of two techniques, RER IL-6/β2-microglobulin and real-time PCR, correlated well (r = 0.98, P < 0.001, log values of real-time PCR data were used). Furthermore, we have found, for the primary glioblastoma tumours included in the present study, a good concordance between RNA expression (RER IL-6/β2-microglobulin) and protein detection using semiquantitative IL-6 immunohistochemistry of neoplastic cells (Rolhion et al, 2001 ). Among primary tumour samples, the highest levels of IL-6 expression were detected in two samples, GBM2 and GBM5, that harboured the highest IL-6 gene copy number. However, GBM1 tumour with a 4-fold overrepresentation of the IL-6 gene showed a weak expression of IL-6 mRNA. All but one tumour cell line showed substantial levels of IL-6 mRNA ( Figure 4) . No IL-6 expression was detected in the SF767 cells that had no IL-6 gene over-representation.
DISCUSSION
The studies described in this paper were initiated in order to estimate the number of IL-6 gene copies in primary cells and cell lines derived from glioblastoma tumours, which frequently show IL-6 over-expression. Using competitive PCR, we found that the number of IL-6 gene copies was increased 3-to 5-fold in 5 of 5 primary tumour samples and 1.5-to 3-fold in 4 of 5 glioblastoma cell lines. This finding was confirmed by means of real-time PCR which has been proven to be the most appropriate method for detecting low-level (≤ 5-fold) gene amplifications (Bièche et al, 1998) . The number of IL-6 gene copies as determined by both methods matched very well. The overrepresentation of IL-6 gene sequences detected in our series of glioblastomas most likely results from amplifications involving the IL-6 gene locus on chromosome 7p21. This hypothesis is supported by the observation that large amplicons on chromosome 7p are present in approximately two-thirds of human glioblastomas . It seems unlikely that the 3-to 5-fold increase in IL-6 gene dosage results from gains of the whole chromosome 7. When the copy number of CFTR gene from chromosome 7q was quantitated, a 1.5-fold increase as compared with normal DNA was found in 3 cases, suggestive of trisomy 7, and a 2.2-fold increase only in 1 case. In most individual cases of glioblastoma tumours and cell lines, the representation of IL-6 gene DNA was obviously higher than that of CFTR gene. Although the number of tumours analysed in our study was small, a high frequency of IL-6 amplification -9 out of 10 cases -suggests that this genetic alteration may be a common feature in glioblastomas.
Amplification may be one of mechanisms mediating the upregulation of IL-6 gene in glioblastomas. In our study, all glioblastomas with amplified IL-6 gene expressed IL-6 mRNA.
Interestingly, a higher level of expression was found in tumours with the highest gene copy number, as measured using two different quantitative RT-PCR approaches. However, no clear correlation could be discerned between IL-6 gene copy number and IL-6 mRNA level in the whole series. Similar observation was reported in breast tumours where MYC gene over-expression did not correlate with DNA over-representation at the MYC locus (Bièche et al, 1999) . In the same way, MDM2 amplification and overexpression did not correlate in adult soft tissue sarcoma (Cordon-Cardo et al, 1994) . The amplified genes may be rearranged, like the EGFR gene in some glioblastoma tumours (Ekstrand et al, 1992) , and therefore may not be over-expressed. These findings are consistent with the idea that not only the increase in gene copy number itself but also changes in the amplicon structure regulate the mRNA expression.
Amplifications of several genes that are implicated in tumour progression characterize glioblastomas (see for review Pathology and Genetics of Tumours of the Nervous System, 2000). In tumour cells, the amplicons containing EGFR, the gene the most frequently amplified in glioblastomas (Canute et al, 1996) , MET (Fischer et al, 1995) , c-MYC (Trent et al, 1986) and GLI (Xiao et al, 1994) are located on double minute chromosomes (DMs). These observations indicate that glioblastomas are susceptible to gene amplifications manifesting as DMs. It is reasonable to hypothesize that IL-6 amplicons are present in glioblastomas on DMs. Indirect evidence for this localization may be provided by the observation that primary tumour cells revealed higher levels of IL-6 amplification than glioblastoma cell lines. As DMs are randomly distributed to daughter cells during division, the change in selection pressure when glioblastoma cells are grown in vitro could reduce the frequency of DMs. We envisage studies using fluorescence in situ hybridization (FISH) with IL-6-gene specific molecular probes to confirm and examine IL-6 gene amplification and its localization. The cell-by-cell analysis using FISH is the most suitable method for this purpose, as amplifications on chromosome 7p in glioblastomas are intratumorally heterogeneous and in some tumours only found in single areas (Jung et al, 1999) .
IL-6 expression appears to be a marker of glioma malignancy that is strongly correlated with tumour aggressiveness and could be considered as a potential therapeutic target. In this regard, further studies of IL-6 gene amplification and amplicon localization on large series of primary tumours are essential to gain information that may be of value for new therapeutic investigations. 
